Literature DB >> 3624313

Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor.

C H Clegg, T A Linkhart, B B Olwin, S D Hauschka.   

Abstract

Analysis of MM14 mouse myoblasts demonstrates that terminal differentiation is repressed by pure preparations of both acidic and basic fibroblast growth factor (FGF). Basic FGF is approximately 30-fold more potent than acidic FGF and it exhibits half maximal activity in clonal assays at 0.03 ng/ml (2 pM). FGF repression occurs only during the G1 phase of the cell cycle by a mechanism that appears to be independent of ongoing cell proliferation. When exponentially growing myoblasts are deprived of FGF, cells become postmitotic within 2-3 h, express muscle-specific proteins within 6-7 h, and commence fusion within 12-14 h. Although expression of these three terminal differentiation phenotypes occurs at different times, all are initiated by a single regulatory "commitment" event in G1. The entire population commits to terminal differentiation within 12.5 h of FGF removal as all cells complete the cell cycle and move into G1. Differentiation does not require a new round of DNA synthesis. Comparison of MM14 behavior with other myoblast types suggests a general model for skeletal muscle development in which specific growth factors serve the dual role of stimulating myoblast proliferation and directly repressing terminal differentiation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3624313      PMCID: PMC2114757          DOI: 10.1083/jcb.105.2.949

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  36 in total

1.  Control of myogenesis in vitro by chick embryo extract.

Authors:  C R Slater
Journal:  Dev Biol       Date:  1976-06       Impact factor: 3.582

2.  Population modeling in muscle cell culture: comparisons with experiments.

Authors:  M C O'Neill
Journal:  Dev Biol       Date:  1976-10-15       Impact factor: 3.582

3.  Diffusion-mediated control of myoblast fusion.

Authors:  I R Konigsberg
Journal:  Dev Biol       Date:  1971-09       Impact factor: 3.582

4.  Clonal analysis of vertebrate myogenesis. VI. Acetylcholinesterase and acetylcholine receptor in myogenic and nonmyogenic clones from chick embryo leg cells.

Authors:  T A Linkhart; S D Hauschka
Journal:  Dev Biol       Date:  1979-04       Impact factor: 3.582

5.  Clonal analysis of vertebrate myogenesis. 3. Developmental changes in the muscle-colony-forming cells of the human fetal limb.

Authors:  S D Hauschka
Journal:  Dev Biol       Date:  1974-04       Impact factor: 3.582

6.  The in vitro cell fusion of embryonic chick muscle without DNA synthesis.

Authors:  J L Doering; D A Fischman
Journal:  Dev Biol       Date:  1974-02       Impact factor: 3.582

7.  Developmental changes preceding cell fusion during muscle differentiation in vitro.

Authors:  D Yaffe
Journal:  Exp Cell Res       Date:  1971-05       Impact factor: 3.905

8.  Influence of environmental factors on the accumulation and differentiation of prefusion G1 lizard myoblasts in vitro.

Authors:  E K Bayne; S B Simpson
Journal:  Exp Cell Res       Date:  1980-05       Impact factor: 3.905

9.  Commitment, fusion and biochemical differentiation of a myogenic cell line in the absence of DNA synthesis.

Authors:  B Nadal-Ginard
Journal:  Cell       Date:  1978-11       Impact factor: 41.582

10.  Effect of fibroblast growth factor on the division and fusion of bovine myoblasts.

Authors:  D Gospodarowicz; J Weseman; J S Moran; J Lindstrom
Journal:  J Cell Biol       Date:  1976-08       Impact factor: 10.539

View more
  133 in total

1.  Atypical protein kinase Cs are the Ras effectors that mediate repression of myogenic satellite cell differentiation.

Authors:  Yuri V Fedorov; Nathan C Jones; Bradley B Olwin
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Expression of a mutant lamin A that causes Emery-Dreifuss muscular dystrophy inhibits in vitro differentiation of C2C12 myoblasts.

Authors:  Catherine Favreau; Dominique Higuet; Jean-Claude Courvalin; Brigitte Buendia
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

3.  Reduced mobility of fibroblast growth factor (FGF)-deficient myoblasts might contribute to dystrophic changes in the musculature of FGF2/FGF6/mdx triple-mutant mice.

Authors:  Petra Neuhaus; Svetlana Oustanina; Tomasz Loch; Marcus Krüger; Eva Bober; Rosanna Dono; Rolf Zeller; Thomas Braun
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

4.  A point mutation in the MyoD basic domain imparts c-Myc-like properties.

Authors:  M E Van Antwerp; D G Chen; C Chang; E V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

5.  Skeletal muscle satellite cells: background and methods for isolation and analysis in a primary culture system.

Authors:  Maria Elena Danoviz; Zipora Yablonka-Reuveni
Journal:  Methods Mol Biol       Date:  2012

6.  The skeletal muscle satellite cell: still young and fascinating at 50.

Authors:  Zipora Yablonka-Reuveni
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

7.  Heparin-binding growth factors and their receptors.

Authors:  B B Olwin
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

8.  MyoD induces growth arrest independent of differentiation in normal and transformed cells.

Authors:  M Crescenzi; T P Fleming; A B Lassar; H Weintraub; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

9.  Expression of avian Ca2+-ATPase in cultured mouse myogenic cells.

Authors:  N J Karin; Z Kaprielian; D M Fambrough
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

10.  Differential trans activation associated with the muscle regulatory factors MyoD1, myogenin, and MRF4.

Authors:  K E Yutzey; S J Rhodes; S F Konieczny
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.